Primary Endpoint Not Met, Safety Profile Remains Similar to Previous Trials

HanAll Biopharma announced on April 2 that its phase 3 clinical trial of batoclimab for patients with thyroid eye disease failed to meet its primary endpoint.

HanAll Biopharma Company Logo Image. HanAll Biopharma

HanAll Biopharma Company Logo Image. HanAll Biopharma

View original image

This clinical trial evaluated the proptosis response rate at 24 weeks after administering high-dose (680 mg) and low-dose (340 mg) batoclimab to adults with active thyroid eye disease for 12 weeks each. However, statistical efficacy was not achieved.


The safety and tolerability profile was similar to previous phase 3 trials for myasthenia gravis and phase 2 trials for Graves' disease, and no newly identified serious adverse events were reported.


The high-dose group showed a trend toward greater improvement in proptosis compared to the low-dose group, and a correlation was observed between the reduction in antibodies and clinical efficacy.


Additionally, among patients with concurrent hyperthyroidism, high-dose administration showed a trend toward normalization of thyroid hormone levels, which is consistent with results observed in the previous phase 2 clinical trial for Graves' disease.


HanAll Biopharma's global partner, Immunovant, is accelerating the development of the next-generation FcRn inhibitor, IMVT-1402. This candidate is characterized by maintaining the effect of reducing antibodies in the body, while minimizing the impact on albumin and improving administration convenience through an auto-injector.



Immunovant is currently conducting clinical trials for six indications and plans to obtain results for refractory rheumatoid arthritis and cutaneous lupus erythematosus this year. Results from a registration trial related to Graves' disease are also expected next year.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing